Business
VALEO PHARMA ANNOUNCES LEADERSHIP CHANGES
VALEO PHARMA ANNOUNCES LEADERSHIP CHANGES.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nVALEO PHARMA ANNOUNCES LEADERSHIP CHANGES\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nVALEO PHARMA ANNOUNCES LEADERSHIP CHANGES\nCanada NewsWire\nMONTREAL, Aug. 6, 2024\n\n\n\nMONTREAL, Aug. 6, 2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, today announced that the Company's Chief Development Officer, Mr. Al Moghaddam, has been appointed to succeed retiring CEO Steve Saviuk.\n\n \n \n \n \n \n \n\n \nMr. Saviuk will remain on Valeo's Board of Directors and assume the role of Chairman.  Mr. Richard J. MacKay will step down from his role of Chairman of the Board and will remain a Board member.\n\"I am enthusiastic to take on the role of CEO of Valeo and lead a talented and dedicated team. Over the past nine months, the company has undergone a transformational restructuring to accelerate its progress towards profitability and continue its development as a leading Canadian pharmaceutical company\", said Al Moghaddam, Valeo's new CEO. \"We have a solid portfolio of innovative products with continued growth potential which we plan to expand upon as we seek to acquire/ in-license additional market ready products\".\n\"We are very pleased with the appointment of Al as CEO. He has the entrepreneurial drive and extensive pharmaceutical background encompassing, commercial operations, strategy, business development and financing, necessary to complete Valeo's transformation\", said Steve Saviuk.\n\"Valeo has grown considerably over the 5 years of my being Chairman. I have had the opportunity and pleasure to work with some talented people within the Company and on the Board and I look forward to continuing to provide guidance in my Board member role\", said Richard J. MacKay, Board member of the Company.\nMore about Al Moghaddam\nMr. Moghaddam is a customer centric transformational life sciences leader with over 25 years of global experience. His work experience spans from large multinationals through to early-stage companies and he has held leadership positions within pharma, med...